Shingrix for Herpes Zoster: A Review

Radhika A Shah1, Allison L Limmer2, Crystal E Nwannunu2

  • 1Texas A&M University College of Medicine, Dallas, TX, USA

Skin Therapy Letter
|July 25, 2019
PubMed
Summary

A new shingles vaccine, HZ/su (Shingrix®), shows high efficacy in preventing herpes zoster (shingles) reactivation in adults over 50. This recombinant subunit vaccine offers a significant reduction in shingles risk for this population.